Literature DB >> 31883407

The molecular biology of medulloblastoma metastasis.

Randy Van Ommeren1,2,3, Livia Garzia4, Borja L Holgado1,2, Vijay Ramaswamy1,2,5, Michael D Taylor1,2,3,6,7.   

Abstract

Medulloblastoma (MB) is the most common primary malignant brain tumor of childhood and a significant contributor to pediatric morbidity and death. While metastatic dissemination is the predominant cause of morbidity and mortality for patients with this disease, most research efforts and clinical trials to date have focused on the primary tumor; this is due mostly to the paucity of metastatic tumor samples and lack of robust mouse models of MB dissemination. Most current insights into the molecular drivers of metastasis have been derived from comparative molecular studies of metastatic and non-metastatic primary tumors. However, small studies on matched primary and metastatic tissues and recently developed mouse models of dissemination have begun to uncover the molecular biology of MB metastasis more directly. With respect to anatomical routes of dissemination, a hematogenous route for MB metastasis has recently been demonstrated, opening new avenues of investigation. The tumor micro-environment of the primary and metastatic niches has also been increasingly scrutinized in recent years, and further investigation of these tumor compartments is likely to result in a better understanding of the molecular mediators of MB colonization and growth in metastatic compartments.
© 2020 International Society of Neuropathology.

Entities:  

Keywords:  extraneural; leptomeninges; medulloblastoma; metastasis; molecular subgroups; therapeutic targets; tumor microenvironment

Mesh:

Year:  2020        PMID: 31883407     DOI: 10.1111/bpa.12811

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  7 in total

1.  ZEB1 is a Subgroup-Specific Marker of Prognosis and Potential Drug Target in Medulloblastoma.

Authors:  Livia Fratini; Matheus Gibeke Siqueira Dalmolin; Marialva Sinigaglia; Alexandre da Silveira Perla; Caroline Brunetto de Farias; Algemir L Brunetto; André T Brunetto; Mariane da Cunha Jaeger; Rafael Roesler
Journal:  Neuromolecular Med       Date:  2022-06-18       Impact factor: 3.843

2.  3D-on-2D: A Physiologically Relevant and Gel-Free In Vitro Coculture Method to Assay Antimetastatic Agents.

Authors:  Abhinav Dey; Samuel Eisenberg; Rayna Birnbaum; David J Sharp
Journal:  Methods Mol Biol       Date:  2022

3.  Tumor-Associated Macrophages Correlate With Prognosis in Medulloblastoma.

Authors:  Jin Zhang; Xia Yuan; Yuan Wang; Jingjing Liu; Zhigang Li; Shuting Li; Yan Liu; Xiaojun Gong; Yanling Sun; Wanshui Wu; Liming Sun; Shuxu Du; Tianyou Wang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

4.  Identification of PBK as a hub gene and potential therapeutic target for medulloblastoma.

Authors:  Yuhao Deng; Huantao Wen; Hanjie Yang; Zhengqiang Zhu; Qiongzhen Huang; Yuewei Bi; Pengfei Wang; Ming Zhou; Jianwei Guan; Wangming Zhang; Min Li
Journal:  Oncol Rep       Date:  2022-05-20       Impact factor: 4.136

Review 5.  Medulloblastoma drugs in development: Current leads, trials and drawbacks.

Authors:  Jiachen Wen; M Kyle Hadden
Journal:  Eur J Med Chem       Date:  2021-02-08       Impact factor: 6.514

6.  A SHHecret target of relapsed medulloblastoma: Astrocytes.

Authors:  Zulekha A Qadeer; William A Weiss
Journal:  J Exp Med       Date:  2021-08-16       Impact factor: 14.307

Review 7.  Role of Circular RNA in Brain Tumor Development.

Authors:  Swalih P Ahmed; Javier S Castresana; Mehdi H Shahi
Journal:  Cells       Date:  2022-07-06       Impact factor: 7.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.